Oculis and Accure Therapeutics have agreed to terms for Oculis to license ACT-01, which is under investigation for the prevention of damage to the optic nerve and retina, according to a press release.
ACT-01, which will be renamed OCS-05, “is a first-in-class small molecule with neuroprotective activity that has shown positive results in animal models of neuroinflammation
and neurodegeneration,” the release said. It is under evaluation in the phase 2a ACUITY study, which is investigating safety and tolerability in patients with acute optic neuritis.
“We are excited about this